GO
Loading...

Actavis Inc

More

  • Actavis' contraceptive device wins U.S. FDA approval Friday, 27 Feb 2015 | 8:10 AM ET

    Feb 27- The U.S. Food and Drug Administration said on Friday it approved a hormonal contraceptive device, providing American women another reversible contraceptive choice as effective as sterilization. Actavis Plc holds the commercial license to the device, the marketing application of which was submitted by non-profit pharmaceutical company...

  • Feb 25- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli& Co analyst Kevin...

  • UPDATE 1-Actavis' superbug antibiotic gets U.S. approval Wednesday, 25 Feb 2015 | 7:50 PM ET

    Feb 25- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli& Co analyst Kevin...

  • TOKYO, Feb 20- Activist investor Daniel Loeb said Fanuc Corp's plan to boost investments was not enough to fix its "blatant capital inefficiency", stepping up calls for the Japanese industrial robot maker to reward shareholders through major buybacks. Loeb, whose hedge fund Third Point holds an undisclosed stake in Fanuc, told Reuters by email the plan to double...

  • NEW YORK, Feb 18- Actavis Plc, a generic drugmaker that has been steadily acquiring branded medicines, said it will change its name to Allergan Inc after it completes its planned $66 billion purchase of the Botox maker, signaling its growing focus on patent-protected drugs. Actavis, which began as a New Jersey- based generics company called Watson, took its current...

  • UPDATE 2-Actavis beats profit estimates, raises forecast Wednesday, 18 Feb 2015 | 9:11 AM ET

    Feb 18- Actavis Plc posted a better-than-expected adjusted quarterly profit and raised its full-year earnings forecast, saying it expected strong sales of its new branded drugs. Actavis agreed to buy Allergan Inc last November for $66 billion, outbidding a hostile offer by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

  • Actavis, which bought Botox-maker Allergan Inc in November, makes drugs from research in its own pipeline, and copy cat versions of other popular drugs. Sales of the Actavis's branded drugs nearly tripled to $1.83 billion in North America in the fourth quarter, accounting for 45 percent of total revenue. For the fourth quarter ended Dec. 31, Actavis's net loss...

  • *Deal builds on last year's purchase of Almirall drugs. LONDON, Feb 5- AstraZeneca has agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial $600 million as it seeks external deals to ensure growth. AstraZeneca will also pay another $100 million, after Actavis agreed to a number of changes to ongoing agreements...

  • LONDON, Feb 5- AstraZeneca said on Thursday it had agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial payment of $600 million as it seeks external deals to ensure growth. The British group, which saw off a $118 billion bid by Pfizer last year, said its sales in the fourth quarter fell 2 percent to $6.68 billion,...

  • Last month's return on Treasuries was the biggest since a 3.54 percent jump in December 2008, according to an index compiled by Bank of America Merrill Lynch. "We are giving back some of the gains from the short-covering rally last week," said Suvrat Prakash, interest rate strategist at HSBC Securities USA in New York. Apple Inc. planned to raise $5 billion in the...

  • Jan 29- Bankrupt drugmaker Dendreon Corp has reached a stalking-horse deal with Canada's Valeant Pharmaceuticals International Inc to sell the worldwide rights to its cancer vaccine, Provenge, and certain assets for $296 million. The deal is subject to higher and better bids and extended the bid deadline to Feb. 10 for interested parties to participate in an...

  • WASHINGTON, Jan 26- The U.S. Supreme Court on Monday sent three patent cases, including one dispute over Shire Plc's Lialda drug, back to a lower court for further proceedings in light of a ruling the justices issued last week. Watson Pharmaceuticals, U.S. Supreme Court, No. 14-206.. Butamax Advanced Fuels LLC and Lighting Ballast Control LLC v.

  • BOSTON, Jan 16- Eric Mindich's $8.5 billion hedge fund, Eton Park Capital Management, is now ready to pick through the debt of beaten-up energy companies, an area it avoided last year as the price of oil tumbled. Eton Park dropped mortgage companies Fannie Mae and Freddie Mac with a big profit before a U.S. judge threw out a lawsuit filed by shareholders to prevent the...

  • SAN FRANCISCO, Jan 15- Allergan Inc Chief Executive David Pyott is close to joining the board of directors of Actavis Plc, which reached a deal to buy the Botox-maker for $66 billion in November, three people familiar with the matter said on Thursday. One investor who attended the meeting told Reuters that adding Pyott to the board could lend more credibility to...

  • *Asset could be worth up to 2 bln euros- Bloomberg. FRANKFURT, Jan 15- German drugmaker Boehringer Ingelheim said it is considering the sale of its U.S.-based generics unit Roxane Labs to put a stronger focus on the development and sale of new pharmaceuticals. A company spokeswoman said Boehringer was not a specialist in generics and was therefore considering...

  • FDA denies approval for Actavis hypertension treatment Wednesday, 24 Dec 2014 | 2:07 PM ET

    Dec 24- Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan. Actavis did not give any further details on the contents of the letter. In a study, the drug combination was found more effective in reducing blood pressure in patients of hypertension,...

  • *Initial jobless claims fall for fourth straight week. *Equity markets close at 1 p.m. in holiday-shortened session. NEW YORK, Dec 24- U.S. stocks edged higher on Wednesday, with the Dow and S&P 500 at records and on track for a sixth straight daily advance as biotech stocks rallied and data pointed to improving economic conditions.

  • NEW YORK, Dec 24- U.S. stocks were set for a modestly higher open on Wednesday on the heels of a five-day winning streak that pushed the Dow and S&P 500 to new closing records and on the latest piece of economic data indicating the economy is strengthening. "Economic data has been consistently positive," said Peter Kenny, chief market strategist at Clearpool Group in...

  • Dec 24- The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.. Memantine is the active ingredient in Actavis' Namenda, while donepezil is the active ingredient in Pfizer Inc's Aricept. Dublin, Ireland- based Actavis said it expects to launch Namzaric in...

  • Actavis, Adamas win FDA approval for Alzheimer's drug Wednesday, 24 Dec 2014 | 8:20 AM ET

    Dec 24- The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.. The drug, Namzaric, is designed to treat moderate-to-severe dementia in Alzheimer's patients who are stabilized with other drugs. Namzaric combines two ingredients in drugs often...